The pioneer in developing therapeutic filtration devices to handle infectious cancers and disease.

Like additional human studies initiated by Aethlon, the pilot study shall be conducted in India, which provides both a proof-of-concept and early commercialization pathway. Aethlon will disclose the website of the pilot study along with treatment protocols in the arriving months. An in vitro research, beneath the collaboration of Douglas D. Taylor, Ph.D. Dr. An in vitro study, under the collaboration of Andrew Raubitschek, M.D. Dr. Raubitschek is also Co-leader for the Malignancy Immunotherapeutics System at the Comprehensive Malignancy Middle and Chief of Radioimmunotherapy and Professor, Radiation Oncology at the City of Hope also..‘We are extremely very happy to receive this positive opinion for Orphan Medication Designation from the EMA for our hESC-derived RPE cells for the treating Stargardt’s disease,’ stated Gary Rabin, ACT’s interim chairman and CEO. ‘There happens to be no accepted treatment for Stargardt’s disease, and we are working diligently to go this European trial forward as quickly as possible. Across from the DuPont Building. The examining will take place on AIDS Healthcare Basis new, state-of-the-artwork ‘Testing America’ cellular HIV testing device named in honor of and together with basketball legend Earvin ‘Magic’ Johnson, Jr. AIDS Healthcare Foundation is definitely proud to continue its second HIV Screening Tour across the US after the effective completion of its latest and ambitious 14 town AHF Magic Johnson HIV Screening Caravan in mid-2009.